Table 3

Outcomes in Subgroups of Interest

CABGPCIHR95% CIInteraction p Value
Patientsn (%)Patientsn (%)
Death, MI, stroke at 1 yr
 2-vessel disease10210 (9.8)908 (8.9)0.90.36–2.280.419
 3-vessel disease14616 (11.0)16425 (15.2)1.420.76–2.67
 BMS group704 (5.7)8213 (15.9)2.990.97–9.160.076
 DES group17822 (12.4)17220 (11.6)0.930.51–1.71
 No insulin15116 (10.6)16117 (10.6)1.020.51–2.010.348
 Insulin9710 (10.3)9216 (17.4)1.670.76–3.67
 Female564 (7.1)7411 (14.9)2.130.68–6.680.289
 Male19222 (11.5)18022 (12.2)1.070.59–1.93
 Age <65 yrs12314 (11.4)11914 (11.8)1.040.49–2.170.497
 Age ≥65 yrs12512 (9.6)13519 (14.1)1.480.72–3.05
Death, MI, stroke, repeat revascularization (MACCE)
 2-vessel disease10210 (9.8)9013 (14.4)1.480.65–3.380.641
 3-vessel disease14618 (12.3)16436 (22.0)1.881.07–3.31
 BMS group705 (7.1)8218 (22.0)3.421.27–9.220.131
 DES group17823 (12.9)17231 (18.0)1.410.82–2.42
 No insulin15118 (11.9)16126 (16.2)1.410.77–2.580.243
 Insulin9710 (10.3)9223 (25.0)2.471.18–5.2
 Female565 (8.9)7415 (20.3)2.40.87–6.610.489
 Male19223 (12.0)18034 (18.9)1.620.95–2.74
 Age <65 yrs12314 (11.4)11921 (17.7)1.580.8–3.10.662
 Age ≥65 yrs12514 (11.2)13528 (20.7)1.941.02–3.68

BMS = bare-metal stent(s); DES = drug-eluting stent(s); MACCE = major adverse coronary and cerebral event; other abbreviations as in Tables 1 and 2.